PF-Atlas › Clinical Trials › NCT07570888
This is a Trial Designed to Evaluate the Combination of Nerandomilast With Mycophenolate Across a Wide Variety of Pulmonary Fibrosis Subtypes, With the Aim of Providing Clinicians With Assurance That This is an Appropriate Therapeutic Combination.
Nerandomilast 18 mg - adult formulation · Phase 4
Registry ID
NCT07570888
Phase
Phase 4
Status
Not yet recruiting
Drug / intervention
Nerandomilast 18 mg - adult formulation
Sponsor
University of British Columbia
Start
2026-06
About this trial
Nerandomilast 18 mg - adult formulation is evaluated in NCT07570888, a Phase 4 idiopathic pulmonary fibrosis study sponsored by University of British Columbia. Current status: Not yet recruiting.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT07570888 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.